Questions around this news
What is precision health?
Precision health uses information about a person or population to help predict health risks, identify disease, and guide prevention or treatment. It can draw on factors such as genetics, medical history, and lifestyle. Its aim is to make care more relevant to individual needs rather than relying only on approaches designed for broad groups.
What actions does the Global Impact Committee’s report call for?
The report urges coordinated work by governments, regulators, and healthcare systems. It frames the goal as making precision health more accessible, trustworthy, and workable across different regions. The release also emphasizes that innovation by itself is not enough: equitable access is needed for communities to share in its potential benefits.
Why does the release highlight gaps in genetic datasets?
The release says Africa has 19% of the global population but is represented in less than 2% of genetic datasets, and warns that regions with limited representation may be left behind. The figures illustrate the report’s concern that precision health could deepen inequity if its evidence base and services are not broadly inclusive.
What does multi-omic data mean in healthcare?
Multi-omic data combines information from several biological layers, such as DNA, gene activity, proteins, or metabolites. Looking across these sources can give researchers and clinicians a broader view of biological processes than examining one type of measurement alone. The methods used to interpret such data can include computational analysis.
November 24, 2025 -- Precision health is advancing at extraordinary speed, reshaping how we predict illness, diagnose disease, and tailor treatment. With gene sequencing costs falling from £2 billion to £230 in just two decades and AI now analysing complex multi-omic data, the potential for personalised, effective care has never been greater. But as the Global Impact Committee’s latest report makes clear, this progress risks deepening inequity unless global systems act now.
The GIC – an independent advisory board supporting Beamtree’s mission to mobilise the power of data for a healthier, happier world – examines both the opportunity and the challenge. As the report states, “The impact of precision health will be as great as medical landmarks such as the discovery of antibiotics and advances in imaging technology.” Yet services remain concentrated in major cities, therapies can cost more than £1.5 million per patient, and entire regions such as Africa, home to 19% of the global population but less than 2% of genetic datasets, are at risk of being left behind.
Beamtree CEO Marek Stepniak emphasises why this work matters: “Precision health represents one of the most profound shifts in modern healthcare. But its true value will only be realised if every community, not just the privileged few, can access the benefits. This report outlines the actions and collaborations needed to ensure precision health becomes equitable, sustainable, and safe at scale.”
The report calls for coordinated action across governments, regulators, and healthcare systems – reforms that can make precision health accessible, trustworthy, and truly global. Its message is clear: innovation alone won’t deliver better outcomes; equitable access will.
Read the full report here to explore the insights and recommendations shaping the future of precision health.
If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.
At a glance
- Company
- Beamtree
Key figures
- Gene sequencing costs, earlier figure
- £2 billion
- Gene sequencing costs, current figure
- £230
- Cost of some therapies per patient
- more than £1.5 million
- Africa's share of global population
- 19%
- Africa's share of genetic datasets
- less than 2%
People
- Marek StepniakBeamtree CEO
